Literature DB >> 28460032

Association of Retinal Architecture, Intrathecal Immunity, and Clinical Course in Multiple Sclerosis.

Benjamin Knier1, Gildas Leppenetier2, Carmen Wetzlmair2, Lilian Aly1, Muna-Miriam Hoshi2, Verena Pernpeintner2, Viola Biberacher2, Achim Berthele2, Mark Mühlau3, Claus Zimmer4, Bernhard Hemmer5, Thomas Korn6.   

Abstract

Importance: Biomarkers to estimate long-term outcomes in patients with multiple sclerosis (MS) and to assign patients to individual treatment regimens are urgently needed. Objective: To assess whether retinal layer volumes are correlated with immune cell subsets and immunoglobulin indices in the cerebrospinal fluid and whether retinal layer volumes alone or in combination with intrathecal variables are associated with worsening of disease in patients with relapsing-remitting MS. Design, Setting, and Participants: This observational cohort study included 312 patients with relapsing-remitting MS in 2 independent cohorts (72 patients with short disease duration [cohort 1] and 240 patients with longer disease duration [cohort 2]) treated at a single German university hospital from April 15, 2013, through November 11, 2015. Main Outcomes and Measures: The common ganglion cell and inner plexiform layer (GCIPL) and inner nuclear layer (INL) volumes were tested for association with the immunoglobulin indices and the frequencies of immune cells in the cerebrospinal fluid (including B cells, T cells, and natural killer cells) (cohort 1). Volumes of GCIPL alone (cohorts 1 and 2) or GCIPL corrected for intrathecal B-cell frequencies (cohort 1) were tested for their association with worsening disability.
Results: A total of 312 patients (212 women [67.9%] and 100 men [32.1%]; median age, 34.0 years [interquartile range (IQR), 28.0-42.0 years]) were available for analysis. In cohort 1 (50 women [69.4%] and 22 men [30.6%]; median age, 31.0 years [IQR, 26.3-38.3 years]), with short disease durations (median, 1.0 months [IQR, 1.0-2.0 months]), low GCIPL volumes were associated with increased intrathecal B-cell frequencies (median, 1.96% [IQR, 1.45%-4.20%]) and intrathecal IgG synthesis (median cerebrospinal fluid/serum IgG index, 0.78 [IQR, 0.53-1.07]). The INL volumes correlated with the frequencies of intrathecal CD56bright natural killer cells (r = 0.28; P = .007). Individuals with low GCIPL volumes (<1.99 mm3) had a 6.4-fold risk for worsening disability during follow-up compared with patients with higher GCIPL values (95% CI, 1.7-24.2; P = .007). This finding was reproduced in cohort 2 (162 women [67.5%] and 78 men [32.5%]; median age, 34.0 years [IQR, 29.0-42.0 years]) consisting of patients with longer disease durations (median, 36.0 months [IQR, 21.0-60.0 months]) (hazard ratio, 2.4; 95% CI, 1.2-4.8; P = .02). In both cohorts, INL volumes correlated with the prospective increase in T2 lesion load and the number of gadolinium-enhancing lesions. Conclusions and Relevance: Retinal layers reflect different aspects of disease activity during MS. Loss of GCIPL is associated with intrathecal B-cell immunity and constitutes an independent risk factor for worsening disability, whereas high INL volumes are associated with activity on magnetic resonance imaging in the brain parenchyma. Thus, retinal optical coherence tomography might be a means to support stratification of patients with MS for different therapeutic regimens.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28460032      PMCID: PMC5822191          DOI: 10.1001/jamaneurol.2017.0377

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  32 in total

1.  In vivo assessment of retinal neuronal layers in multiple sclerosis with manual and automated optical coherence tomography segmentation techniques.

Authors:  Michaela A Seigo; Elias S Sotirchos; Scott Newsome; Aleksandra Babiarz; Christopher Eckstein; E'tona Ford; Jonathan D Oakley; Stephanie B Syc; Teresa C Frohman; John N Ratchford; Laura J Balcer; Elliot M Frohman; Peter A Calabresi; Shiv Saidha
Journal:  J Neurol       Date:  2012-03-15       Impact factor: 4.849

2.  A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis.

Authors:  Roberta Magliozzi; Owain W Howell; Cheryl Reeves; Federico Roncaroli; Richard Nicholas; Barbara Serafini; Francesca Aloisi; Richard Reynolds
Journal:  Ann Neurol       Date:  2010-10       Impact factor: 10.422

Review 3.  Human CD56bright NK Cells: An Update.

Authors:  Tatiana Michel; Aurélie Poli; Angelica Cuapio; Benjamin Briquemont; Gilles Iserentant; Markus Ollert; Jacques Zimmer
Journal:  J Immunol       Date:  2016-04-01       Impact factor: 5.422

4.  Intra- and interscanner variability of magnetic resonance imaging based volumetry in multiple sclerosis.

Authors:  Viola Biberacher; Paul Schmidt; Anisha Keshavan; Christine C Boucard; Ruthger Righart; Philipp Sämann; Christine Preibisch; Daniel Fröbel; Lilian Aly; Bernhard Hemmer; Claus Zimmer; Roland G Henry; Mark Mühlau
Journal:  Neuroimage       Date:  2016-07-16       Impact factor: 6.556

5.  Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome.

Authors:  W J Brownlee; D R Altmann; P Alves Da Mota; J K Swanton; K A Miszkiel; Cam Gandini Wheeler-Kingshott; O Ciccarelli; D H Miller
Journal:  Mult Scler       Date:  2016-08-06       Impact factor: 6.312

6.  Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis.

Authors:  S Cepok; M Jacobsen; S Schock; B Omer; S Jaekel; I Böddeker; W H Oertel; N Sommer; B Hemmer
Journal:  Brain       Date:  2001-11       Impact factor: 13.501

7.  Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study.

Authors:  Shiv Saidha; Elias S Sotirchos; Mohamed A Ibrahim; Ciprian M Crainiceanu; Jeffrey M Gelfand; Yasir J Sepah; John N Ratchford; Jiwon Oh; Michaela A Seigo; Scott D Newsome; Laura J Balcer; Elliot M Frohman; Ari J Green; Quan D Nguyen; Peter A Calabresi
Journal:  Lancet Neurol       Date:  2012-10-04       Impact factor: 44.182

8.  Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.

Authors:  Xavier Montalban; Giancarlo Comi; Jack Antel; Paul O'Connor; Ana de Vera; Malika Cremer; Nikolaos Sfikas; Philipp von Rosenstiel; Ludwig Kappos
Journal:  J Neurol       Date:  2015-09-04       Impact factor: 4.849

9.  Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning.

Authors:  John N Ratchford; Shiv Saidha; Elias S Sotirchos; Jiwon A Oh; Michaela A Seigo; Christopher Eckstein; Mary K Durbin; Jonathan D Oakley; Scott A Meyer; Amy Conger; Teresa C Frohman; Scott D Newsome; Laura J Balcer; Elliot M Frohman; Peter A Calabresi
Journal:  Neurology       Date:  2013-01-01       Impact factor: 9.910

10.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

View more
  11 in total

1.  Retinal Tissue Perfusion in Patients with Multiple Sclerosis.

Authors:  Yi Liu; Silvia Delgado; Hong Jiang; Ying Lin; Jeffrey Hernandez; Yuqing Deng; Giovana Rosa Gameiro; Jianhua Wang
Journal:  Curr Eye Res       Date:  2019-05-15       Impact factor: 2.424

Review 2.  Optical coherence tomography in multiple sclerosis.

Authors:  Josefine Britze; Jette Lautrup Frederiksen
Journal:  Eye (Lond)       Date:  2018-02-02       Impact factor: 3.775

Review 3.  What Does Optical Coherence Tomography Offer for Evaluating Physical Disability in Patients with Multiple Sclerosis?

Authors:  Ziya Ayhan; Aylin Yaman
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

4.  Optical Coherence Tomography and Optical Coherence Tomography Angiography Findings in Multiple Sclerosis Patients.

Authors:  Ayşe Balıkçı; Neslihan Parmak Yener; Meral Seferoğlu
Journal:  Neuroophthalmology       Date:  2021-08-20

5.  Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple Sclerosis.

Authors:  Jeffrey Lambe; Kathryn C Fitzgerald; Olwen C Murphy; Angeliki G Filippatou; Elias S Sotirchos; Grigorios Kalaitzidis; Elena Vasileiou; Nicole Pellegrini; Esther Ogbuokiri; Brandon Toliver; Nicholas J Luciano; Simidele Davis; Nicholas Fioravante; Ohemaa Kwakyi; Hunter Risher; Ciprian M Crainiceanu; Jerry L Prince; Scott D Newsome; Ellen M Mowry; Shiv Saidha; Peter A Calabresi
Journal:  Neurology       Date:  2021-03-02       Impact factor: 9.910

6.  Evaluation of Retinal Layer Thickness Parameters as Biomarkers in a Real-World Multiple Sclerosis Cohort.

Authors:  Natascha Schurz; Lydia Sariaslani; Patrick Altmann; Fritz Leutmezer; Christoph Mitsch; Berthold Pemp; Paulus Rommer; Tobias Zrzavy; Thomas Berger; Gabriel Bsteh
Journal:  Eye Brain       Date:  2021-03-12

7.  Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis.

Authors:  Lilian Aly; Christina Noll; Rebecca Wicklein; Elisabeth Wolf; Eva Feodora Romahn; Josphine Wauschkuhn; Sami Hosari; Christian Mardin; Achim Berthele; Bernhard Hemmer; Thomas Korn; Benjamin Knier
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-03-17

8.  Longitudinal retinal imaging study of newly diagnosed relapsing-remitting multiple sclerosis in Scottish population: baseline and 12 months follow-up profile of FutureMS retinal imaging cohort.

Authors:  Yingdi Chen; Juan Larraz; Michael Wong; Patrick Kearns; Fraser Brown; Sarah-Jane Martin; Peter Connick; Niall MacDougall; Christine Weaver; Baljean Dhillon; Siddharthan Chandran
Journal:  BMJ Open Ophthalmol       Date:  2022-07

9.  Increased Serum Neurofilament Light and Thin Ganglion Cell-Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis.

Authors:  Ting-Yi Lin; Viktoriya Vitkova; Susanna Asseyer; Ivette Martorell Serra; Seyedamirhosein Motamedi; Claudia Chien; Marc Ditzhaus; Athina Papadopoulou; Pascal Benkert; Jens Kuhle; Judith Bellmann-Strobl; Klemens Ruprecht; Friedemann Paul; Alexander U Brandt; Hanna G Zimmermann
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-08-04

10.  Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders.

Authors:  Lilian Aly; Eva-Maria Strauß; Nikolaus Feucht; Isabella Weiß; Achim Berthele; Meike Mitsdoerffer; Christian Haass; Bernhard Hemmer; Mathias Maier; Thomas Korn; Benjamin Knier
Journal:  Mult Scler       Date:  2021-07-14       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.